Evotecs herausfordernder Jahresstart: Umbaukosten und Marktbedingungen belasten das Ergebnis

A Difficult Start to 2023

Evotec, a significant player in pharmaceutical active ingredient research and development, has had a weaker-than-expected start to 2023. High restructuring costs have significantly burdened the results. In the first quarter, adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) fell from 3.1 million euros in the previous year to a concerning minus 21.9 million euros. This development clearly shows that analysts‘ expectations have not been met.

Decline in Revenue and One-Time Effects

The company’s revenue decreased by more than 20 percent compared to the previous year, totaling nearly 157 million euros. Here too, analysts had anticipated significantly higher figures. CEO Christian Wojczewski described the start of the year as „expected,“ but pointed to a significant one-time effect in the previous year due to additional licensing revenues. Additionally, currency effects and a cautious business development in certain areas are currently weighing on results.

Outlook for the Second Half of the Year

Despite the challenging situation, Wojczewski remains optimistic about the second half of the year. He expects a recovery in the market environment that could positively impact business development. The package of measures implemented under the cost-saving program „Horizon“ is on track and is expected to lead to noticeable effects throughout the year.

Long-Term Revenue Forecasts

For the year 2026, Evotec still aims for revenue between 700 and 780 million euros, even though the previous year’s revenue was around 788 million euros. The adjusted operating result (EBITDA) is projected to be between 0 and 40 million euros, down from about 41 million euros in 2025. Analysts estimate that the company will be able to reach the midpoint of this forecast range.

Comprehensive Cost-Cutting Measures and Location Changes

At the beginning of April, Evotec announced that 2023 would be a „transitional year“ with comprehensive cost-cutting measures. The number of locations is to be reduced to ten, and further job cuts of up to 800 positions are planned. This program is expected to be largely implemented by the end of 2027 and aims to achieve sustainable savings of around 75 million euros. In parallel, Evotec is currently reviewing „strategic options“ without providing specific details.

Overall, Evotec’s situation illustrates the importance of flexibility and adaptability in a rapidly changing market. The challenges the company faces could also present long-term opportunities for investors interested in the company’s innovative strength and growth potential.